<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000177.pub2" GROUP_ID="STROKE" ID="081699073114514330" MERGED_FROM="" MODIFIED="2008-09-17 16:21:25 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-09-17 16:21:25 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Prostacyclin and analogues for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2008-09-17 16:21:25 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7166" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>MW</MIDDLE_INITIALS><LAST_NAME>Bath</LAST_NAME><SUFFIX>FRCP</SUFFIX><POSITION>Stroke Association Professor of Stroke Medicine</POSITION><EMAIL_1>philip.bath@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07798 670726</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>South Block D Floor</ADDRESS_1><ADDRESS_2>Queens Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1768</PHONE_1><FAX_1>+44 115 823 1767</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-17 16:21:25 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7166" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>MW</MIDDLE_INITIALS><LAST_NAME>Bath</LAST_NAME><SUFFIX>FRCP</SUFFIX><POSITION>Stroke Association Professor of Stroke Medicine</POSITION><EMAIL_1>philip.bath@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07798 670726</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>South Block D Floor</ADDRESS_1><ADDRESS_2>Queens Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1768</PHONE_1><FAX_1>+44 115 823 1767</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-17 14:53:04 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="16" MONTH="3" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-17 14:53:25 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-17 15:11:38 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-17 15:11:38 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="16" MONTH="3" YEAR="2004"/>
<DESCRIPTION>
<P>November 2003</P>
<UL>
<LI>Further search.</LI>
<LI>Addition of two excluded trials (Hakim 1984; Isaka 1990).</LI>
<LI>Minor changes to text</LI>
</UL>
<P>January 1998</P>
<UL>
<LI>Further search</LI>
<LI>Addition of an excluded trial (Zhao 1991)</LI>
<LI>Exclusion of the trial of Mizushima (Mizushima 1994) since no data have been made available by the authors</LI>
</UL>
<P>January 1996</P>
<UL>
<LI>Further information on the trial of Hsu et al (Hsu 1986) obtained from an internal Upjohn Company report</LI>
<LI>Data from the trial of Pokrupa and colleagues (Pokrupa 1986) made available as individual patient data and from an unpublished manuscript</LI>
</UL>
<P>NOTE: This review covers an area where no active research is taking place. It will be updated if relevant information becomes available, e.g. on completion of an appropriate study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Wolfson Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>South Thames NHS R&amp;D Executive</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Stroke Association</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-17 15:16:19 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-09-17 14:55:51 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-09-17 14:55:51 +0100" MODIFIED_BY="Hazel Fraser">Prostacyclin and analogues for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-17 14:55:41 +0100" MODIFIED_BY="Hazel Fraser">
<P>Prostacyclin and related drugs, which can dilate brain blood vessels, are of no apparent benefit in the early treatment of strokes caused by blood clots. Most strokes are caused by a blood clot which then reduces blood flow in the affected part of the brain. Without an adequate blood supply, the brain quickly suffers damage which is often permanent. Drugs which can thin blood and improve brain blood flow might reduce damage and improve outcome after stroke. Prostacyclin and related drugs have the ability to thin blood and increase brain blood flow. This systematic review assesses whether this type of drug improves outcome after stroke. The review identified five small trials which, when taken together, did not find any benefit. The limited amount of data mean that there is no evidence at present to suggest that prostacyclin and related drugs should be used in acute stroke.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-17 14:55:16 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2008-09-17 14:55:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Prostacyclin is an agent with a number of effects on platelets, blood vessels and nerve cells which might improve outcome after acute ischaemic stroke. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-09-17 14:55:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effect of prostacyclin or analogues on survival in people with acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group Trials Register (last searched November 2003). For the first version, we also searched EMBASE (1980 to 1999), MEDLINE (1966 to 1999), Science Citation Index (1981 to 1999) and the Ottawa Stroke Trials Registry. We also contacted the manufacturers of prostacyclin and the principal investigators of the identified trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing prostacyclin or analogues with placebo or control. Trials where people were entered within one week of stroke onset were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Information on the methods of randomisation, blinding, analysis, the number of patients randomised, dose and timing of prostacyclin or analogue, patient withdrawals, the number of deaths occurring in each trial, and trial quality, were collected and assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Five trials involving 191 people were included. Six early deaths (within four weeks) occurred with prostacyclin, and nine with placebo (odds ratio (OR) 0.63, 95% confidence interval (CI) 0.22 to 1.85). One trial of 32 patients reported late deaths (by 10 to 18 months) in 50% of patients in each group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Too few patients have been studied in randomised trials to allow conclusions to be drawn about the effect of prostacyclin treatment on survival of people with acute stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-17 15:16:19 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Stroke is the third most common cause of death in the Western world and the most common cause of long-term adult disability. However, no acute therapeutic intervention has yet been shown to be effective in reducing mortality or morbidity. Prostacyclin is an endothelium-derived prostenoid which has vasodilating, antiplatelet (<LINK REF="REF-Moncada-1983" TYPE="REFERENCE">Moncada 1983</LINK>), antileucocyte (<LINK REF="REF-Bath-1991" TYPE="REFERENCE">Bath 1991</LINK>), fibrinolytic and cytoprotective effects. Prostacyclin synthesis appears to be reduced in stroke (<LINK REF="REF-Gryglewski-1982" TYPE="REFERENCE">Gryglewski 1982</LINK>) whilst cerebral infarction is characterised by thrombosis, platelet and leucocyte aggregation, and leucocyte infiltration. Hence, prostacyclin is a candidate treatment for acute ischaemic stroke.</P>
<P>Pre-clinical studies suggest that prostacyclin may be effective in animal models of cerebral infarction (e.g. <LINK REF="REF-Akopov-1992" TYPE="REFERENCE">Akopov 1992</LINK>). Several non-randomised trials of prostacyclin in acute ischaemic stroke have been reported which suggest that prostacyclin reduces morbidity following stroke and is safe to administer (<LINK REF="REF-Gryglewski-1982" TYPE="REFERENCE">Gryglewski 1982</LINK>; <LINK REF="REF-Gryglewski-1983" TYPE="REFERENCE">Gryglewski 1983</LINK>; <LINK REF="STD-Hakim-1984" TYPE="STUDY">Hakim 1984</LINK>; <LINK REF="REF-Miller-1984" TYPE="REFERENCE">Miller 1984</LINK>; <LINK REF="REF-Miller-1985" TYPE="REFERENCE">Miller 1985</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>). As a result, a number of randomised controlled trials in acute ischaemic stroke have been undertaken. This Cochrane review presents an overview analysis of these randomised controlled trials.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether prostacyclin is a safe treatment for patients with ischaemic stroke when administered acutely and whether it reduces the risk of early and late death.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-17 14:58:00 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled parallel group trials examining the effects of prostacyclin administered within one week of acute presumed ischaemic stroke.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with acute stroke, where attempts were made to exclude primary intracerebral haemorrhage, were included in the analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intravenous prostacyclin or analogue versus placebo. The analogues considered were: TRK-100, ONO-41483, HOE 892, OP-2507 and ZK 36374.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome measure was the frequency of early (within one month) death. The only secondary outcome was late (within eighteen months) death from all causes. Morbidity was not analysed since the trial publications do not give sufficient information.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-17 14:57:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group trials register, which was last searched by the Review Group Co-ordinator in November 2003.</P>
<P>For the first version of this review, we also searched EMBASE (1980 to 1999), MEDLINE (1966 to 1999), Science Citation Index (1981 to 1999), and the Ottawa Stroke Trials Registry. Electronic search terms included: (stroke or cerebr*) and (prostacyclin or epoprostenol or ciprostene or clioprost or iloprost or isocarbacyclin or beraprost or TRK-100 or ONO-41483 or HOE 892 or OP-2507 or ZK 36374); the latter compounds are analogues of prostacyclin.</P>
<P>In an effort to identify unpublished trials, we contacted the manufacturers of prostacyclin: Wellcome Foundation, UK, and Upjohn Company, UK. Additional information was sought from the principal investigators of the identified trials. Reviews of prostacyclin in cerebrovascular disease were also searched (<LINK REF="REF-Chen-1986" TYPE="REFERENCE">Chen 1986</LINK>; <LINK REF="REF-Martindale-1993" TYPE="REFERENCE">Martindale 1993</LINK>; <LINK REF="REF-Moncada-1983" TYPE="REFERENCE">Moncada 1983</LINK>). Note: prostacyclin was first identified in 1976 and studied in man in 1978.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-17 14:58:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>We (PB, FB) selected trials for inclusion in the review and sought additional information from the principal investigators of all trials that appeared to meet the inclusion criteria.</P>
<P>We noted information on the methods of randomisation, blinding, analysis, the number of patients randomised, dose and timing of prostacyclin or analogue, patient withdrawals, and the number of deaths occurring in each trial. The primary outcome was early (within one month) death.</P>
<P>We tested for heterogeneity and calculated a weighted estimate of the typical treatment effect across trials (odds ratio) using the Cochrane Review Manager software, RevMan 4.2.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-17 15:09:58 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-09-17 14:58:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>Five trials, each of which used sodium prostacyclin, met our inclusion criteria and have been included in the analysis, as summarised in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. One further trial of 427 patients, published within a paper which also describes several non-stroke studies, involved the administration of a prostacyclin analogue (<LINK REF="STD-Mizushima-1994" TYPE="STUDY">Mizushima 1994</LINK>); this trial has been excluded as no information has been received from the authors. Altogether, five trials were excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>The average age of the patients in the trials was approximately 65 years, and slightly more men than women were included.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-17 14:59:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>Prostacyclin caused frequent but essentially mild adverse effects (e.g. headaches, nausea, 'warmth', dizziness, and facial flushing); as a result, it is unlikely that any of the trials of prostacyclin were ever truly blinded since both patients and staff may have been aware whether drug or placebo was administered. Two trials used independent neurological assessors who were not present during infusions to minimise bias in outcome assessment (<LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>); at present, this is of no relevance to this review because death is the only available outcome.</P>
<P>Three of the included trials delayed administration of prostacyclin until after 24 hours following stroke onset to exclude patients with transient ischaemic attack. Hsu studied all patients within 24 hours (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>) whilst Pokrupa included patients up to 48 hours post-ictus (<LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>). Only one trial reported deaths at one year (<LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>). Three trials used CT scans to exclude cerebral haemorrhage (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>; <LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>); the other two used a combination of EEG and CSF analysis (<LINK REF="STD-Huczynski-1985" TYPE="STUDY">Huczynski 1985</LINK>; <LINK REF="STD-Huczynski-1988" TYPE="STUDY">Huczynski 1988</LINK>) which means that some patients with primary intracerebral haemorrhage may have inadvertently been studied.</P>
<P>One trial randomised patients by sealed numbered opaque envelope (<LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>); the other trial reports do not give explicit information on how randomisation was undertaken although all declare they were randomised. Furthermore, none of the studies explicitly state that they were analysed by intention to treat; however, it is clear in three trials that no patients were lost to follow up (<LINK REF="STD-Huczynski-1985" TYPE="STUDY">Huczynski 1985</LINK>; <LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>). However, we have performed an intention-to-treat analysis since outcome data relating to deaths are available for all patients whether withdrawn from treatment or not.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-17 15:09:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>The total number of participants included in the five analysed trials amounted to 191. There was no evidence of statistical heterogeneity in the analysis (Chi = 0.78, 2P &gt; 0.1). The five trials showed a non-significant 37% reduction in the odds of early death (within one month) (95% confidence interval (CI), 78% reduction to 85% excess); however, this difference is due to three less deaths in the prostacyclin group across two trials (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>). Only one trial assessed late deaths (total deaths at 10 to 18 months) and found no difference although the confidence intervals were wide (<LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>).</P>
<P>Prostacyclin is a vasodilator which induces dose-dependent falls in blood pressure. Hypotension during the acute phase of stroke may be associated with poor outcome (<LINK REF="REF-Bath-1995" TYPE="REFERENCE">Bath 1995</LINK>). Four of the trials reported the effect of prostacyclin on blood pressure; Martin and Pokrupa found no statistical difference between active and placebo groups with respect to blood pressure and heart rate (<LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>; <LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>). Two patients receiving prostacyclin in the former study had to have the dose halved because of hypotension (<LINK REF="STD-Martin-1985" TYPE="STUDY">Martin 1985</LINK>). In contrast, Hsu reported that prostacyclin reduced blood pressure and increased heart rate (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>). Although Huczynski did not compare active and placebo groups, one patient receiving prostacyclin was withdrawn from the trial because of hypotension (<LINK REF="STD-Huczynski-1988" TYPE="STUDY">Huczynski 1988</LINK>). One trial found that facial flushing, a recognised adverse effect of prostacyclin, occurred in six patients receiving active medication but none taking placebo (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>). Eleven patients in one study had the prostacyclin infusion rate reduced due to the development of adverse effects (<LINK REF="STD-Pokrupa-1986" TYPE="STUDY">Pokrupa 1986</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-17 15:16:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>This review analyses apparently randomised controlled trials of intravenous prostacyclin in acute ischaemic stroke. The results do not support the hypothesis that prostacyclin reduces early all cause case fatality. However, the confidence intervals are wide reflecting the low numbers of patients studied, and prostacyclin could equally reduce short-term case fatality by 78% or increase it by 85%. One trial examined the effect of prostacyclin on late deaths and found no difference. The protocols used can be criticised in the light of current practice. Firstly, prostacyclin was only administered to all patients within 24 hours of stroke onset in one trial; three other trials delayed treatment beyond 24 hours when ischaemic damage is likely to be fixed and not amenable to pharmacological intervention. Secondly, prostacyclin was administered discontinuously in four trials leading to the potential for rebound vasoconstriction and platelet/leucocyte activation between infusions. Thirdly, two trials used EEG and CSF criteria to exclude primary intracerebral haemorrhage which raises the possibility that patients with haemorrhage were included. Lastly, it is currently unclear how patients were randomised in four of the five studies.</P>
<P>In spite of the biological rationale for administering prostacyclin in acute ischaemic stroke, it is also possible that it may worsen outcome since infusions in normal people paradoxically reduce cerebral blood flow (<LINK REF="REF-Brown-1982" TYPE="REFERENCE">Brown 1982</LINK>; <LINK REF="REF-Cook-1983" TYPE="REFERENCE">Cook 1983</LINK>).</P>
<P>In summary, analysis of five trials of prostacyclin do not show evidence that it reduces case fatality following acute presumed ischaemic stroke. However, the numbers of trials and participants studied were too small and trial designs were suboptimal so that further research is required.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Prostacyclin should not currently be used in the routine management of acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The existing trials show no evidence that prostacyclin is harmful or beneficial in patients with acute ischaemic stroke. However, the trials included few patients and mostly administered prostacyclin late (after 24 hours) and in a discontinuous fashion. Hence, one or more larger trials of prostacyclin, or a longer acting analogue, are warranted in acute ischaemic stroke. It is suggested that a new trial might enrol upwards of 2000 patients within 12 hours of the onset of ischaemic stroke. Prostacyclin or analogue should be infused over five days continuously, as in (<LINK REF="STD-Hsu-1986" TYPE="STUDY">Hsu 1986</LINK>), to prevent potential rebound platelet hyperfunction (<LINK REF="REF-Sinzinger-1981" TYPE="REFERENCE">Sinzinger 1981</LINK>) and perhaps reduce adverse effects. Aspirin would be given to all patients, as is standard now, with the benefit of inhibiting the endogenous synthesis of vasoconstricting proaggregatory prostenoids (e.g. thromboxane A2) (<LINK REF="STD-Huczynski-1988" TYPE="STUDY">Huczynski 1988</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-09-17 15:12:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>We are grateful to Dr Wojtek Rakowicz for translating the Polish language paper, Dr David Moher of the Ottawa Stroke Trials Registry for helping to identify relevant trials, the individual prostacyclin trialists for providing further information, and to the Cochrane Stroke Group Editorial Board and external peer reviewers for making constructive comments on this review. Dr Philip Bath was Wolfson Senior Lecturer in Stroke Medicine, and is Stroke Association Professor of Stroke Medicine. Dr Fiona Bath contributed (co-ordination, searching, data collation, management, entry, and analysis) to the first version of the review.</P>
<SUBSECTION>
<HEADING LEVEL="2">Ongoing trials</HEADING>
<P>We are not aware of any ongoing trials of prostacyclin or analogues and would be grateful to be informed of any, or of any other relevant trials not covered here.</P>
</SUBSECTION>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-17 15:00:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-17 15:00:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Philip Bath: conceived and designed the review, developed the search strategy, interpreted the data, wrote and updated the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>NOTE: This review covers an area where no active research is taking place. It will be updated if relevant information becomes available, e.g. on completion of an appropriate study.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-17 15:09:21 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-09-17 15:08:15 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-09-17 15:07:12 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="MIX" ID="STD-Hsu-1986" MODIFIED="2008-09-17 15:07:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hsu 1986" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hsu CY, Faught Jn RE, Furlan AJ, Coull BM, Huang EL, Hogan EL, et al</AU>
<TI>Intravenous prostacyclin in acute nonhemorrhagic stroke: a placebo-controlled double-blind trial</TI>
<SO>Stroke</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>352-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kent IC, Huang DC, Linet OI</AU>
<TI>Randomized, controlled clinical trial of Cyclo-prostin (epoprostenol, prostacyclin, PGI2) in acute atherothrombotic strokes and embolic strokes of cardiac origin (multi-clinic protocol 1088 - Investigators: Drs Coull, Faught, Furlan, Hogan, and Yatsu)</TI>
<SO>Upjohn Company Technical Report 7250/85/007</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linet O, Hsu CY, Faught RE, Hogan EL, Furlan AJ, Coull BM, et al</AU>
<TI>Epoprostenol in acute stroke</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>149</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-17 15:07:12 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yatsu FM, Grotta JC, Pettigrew LC, Gray CS</AU>
<TI>Prostacylin infusion for acute ischaemic strokes: Results of a double-blind study</TI>
<SO>Acute brain ischaemia: medical and surgical therapy</SO>
<YR>1986</YR>
<PG>263-271</PG>
<EN>1st</EN>
<ED>Battistini N, Fiorani P, Courbier R, Plum F, Fieschi C</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-17 15:07:01 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yatsu FM, Grotta JC, Pettigrew LC, Gray JD, Hogan EL, Hsu CY, et al</AU>
<TI>Prostacyclin infusions in acute ischaemic strokes. Royal Society of Medicine Services International Congress and Symposium Series No 99</TI>
<SO>Stroke: epidemiological, therapeutic and socio-economic aspects</SO>
<YR>1986</YR>
<PG>73-9</PG>
<EN>1st</EN>
<ED>Clifford Rose F</ED>
<PB>Royal Society of Medicine Services Limited</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huczynski-1985" MODIFIED="2008-09-17 15:06:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Huczynski 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-17 15:06:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huczynski J, Kostka-Trabka E, Sotowska W, Bieron K, Grodzinska L, Dembinska-Kiec A, et al</AU>
<TI>Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>810-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huczynski-1988" MODIFIED="2008-09-17 15:06:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Huczynski 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-09-17 15:06:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huczynski J, Gryglewski RJ, Kostka-Trabka E, Dembinska-Kiec A, Pykosz-Mazur E, Sotowska W, et al</AU>
<TI>Use of prostacyclin in patients with ischemic stroke. A double-blind method II</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>1988</YR>
<VL>22</VL>
<PG>299-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1985" NAME="Martin 1985" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamdy NAT, Martin JF, Nicholl J, Owen P, Lewtas N, Bergvall UB, et al</AU>
<TI>Controlled trial of prostacyclin in acute cerebral infarction</TI>
<SO>Clinical Science</SO>
<YR>1984</YR>
<VL>66 (Suppl)</VL>
<PG>48P</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin JF, Hamdy N, Nicholl J, Lewtas N, Bergvall U, Owen P, et al</AU>
<TI>Prostacyclin in cerebral infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1985</YR>
<VL>312</VL>
<PG>1642</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martin JF, Handy N, Nicholl J, Lewtas N, Bergvall U, Owen P, et al</AU>
<TI>Double-blind controlled trial of prostacyclin in cerebral infarction</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pokrupa-1986" NAME="Pokrupa 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pokrupa A, Hakim J, Villanueva G, Francis G, Wolfe L</AU>
<TI>Clinical study of prostacyclin infusion after acute ischemic stroke</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pokrupa R, Hakim A, Villanueva J, Meyer E, Diksic M, Evans A</AU>
<TI>PET evaluation of blood flow and metabolic changes induced by PGI2 therapy in patients with ischemic stroke</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Pokrupa RP, Hakim AM, Villanueva JA, Diksic M, Evans AE, Meyer E, et al</AU>
<TI>Prostacyclin infusion after acute cerebral infarction: clinical and PET studies</TI>
<SO>Unpublished manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-17 15:08:15 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Hakim-1984" MODIFIED="2008-09-17 15:08:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hakim 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-09-17 15:08:03 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim AM, Pokrupa RP, Wolfe LS</AU>
<TI>Preliminary report on the effectiveness of prostacylin in stroke</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>3</NO>
<PG>409 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 15:08:03 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoshi-1990" NAME="Hoshi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoshi K, Mizushima Y</AU>
<TI>A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction</TI>
<SO>Prostaglandins</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>2</NO>
<PG>155-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isaka-1990" MODIFIED="2008-09-17 15:08:15 +0100" MODIFIED_BY="Hazel Fraser" NAME="Isaka 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-17 15:08:15 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaka Y, Imaizumi M, Mieno M, Uehara A, Hashikawa K, Handa N, et al</AU>
<TI>Potency of TRK-100 (oral active prostacyclin analogue) as an antiplatelet agent as assessed by indium 111 platelet scintigraphy</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21(suppl 1)</VL>
<NO>8</NO>
<PG>I-160 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 15:08:15 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mizushima-1994" NAME="Mizushima 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizushima Y, Toyota T, Okita K, Ohtomo E</AU>
<TI>Recent clinical studies on lipo-PGE1 and lipo-PGI2: PGE1 and PGI2 incorporated in lipid microspheres, for targeted delivery</TI>
<SO>Journal of Controlled Release</SO>
<YR>1994</YR>
<VL>28</VL>
<PG>243-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-1991" NAME="Zhao 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao J</AU>
<TI>Treatment of acute cerebral infarction with PGI2 - evaluating the clinical effect and observation of dynamic changes in plasma TXB2 and 6-keto PGF1 alpha levels</TI>
<SO>Chung Hua Shen Ching Ching Shen Ko Tsa Chih</SO>
<YR>1991</YR>
<VL>24</VL>
<PG>138-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-17 15:09:21 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-17 15:09:21 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Akopov-1992" NAME="Akopov 1992" TYPE="JOURNAL_ARTICLE">
<AU>Akopov S, Ghazarian A, Gabrielian E</AU>
<TI>Effects of nimodipine and nicergolin on cerebrovascular injuries induced by activation of platelets and leukocytes in vivo</TI>
<SO>Archives Internationales de Pharmacodynamie et de Therapie</SO>
<YR>1992</YR>
<VL>318</VL>
<PG>66-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1991" MODIFIED="2008-09-17 15:08:30 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bath PMW, Hassall DG, Gladwin A-M, Palmer RMJ, Martin JF</AU>
<TI>Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro</TI>
<SO>Arteriosclerosis and Thrombosis</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1995" MODIFIED="2008-09-17 15:09:21 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 1995" TYPE="COCHRANE_REVIEW">
<AU>Bath PMW, Bath FJ</AU>
<TI>Blood pressure management in acute stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1995</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1982" NAME="Brown 1982" TYPE="JOURNAL_ARTICLE">
<AU>Brown MM, Pickles H</AU>
<TI>Effect of epoprostenol (prostacyclin, PGI2) on cerebral blood flow in man</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1982</YR>
<VL>45</VL>
<PG>1033-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1986" MODIFIED="2008-09-17 15:08:33 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 1986" TYPE="JOURNAL_ARTICLE">
<AU>Chen ST, Hsu CY, Hogan EL, Halushka PV, Linet OI, Yatsu FM</AU>
<TI>Thromboxane, prostacyclin, and leukotrienes in cerebral ischemia</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>466-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cook-1983" NAME="Cook 1983" TYPE="JOURNAL_ARTICLE">
<AU>Cook PJ, Maidment CG, Dandona P, et al</AU>
<TI>The effect of intravenous epoprostenol (prostacyclin, PGI2) on cerebral blood flow and cardiac output in man</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>707-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryglewski-1982" NAME="Gryglewski 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gryglewski RJ, Nowak S, Kostka-Trabka E, Bieron K, Dembinska-Kiec A, Blaszczyk B, Kusmiderski J, Markowska E, Szmatola S</AU>
<TI>Clinical use of prostacyclin (PGI2) in ischaemic stroke</TI>
<SO>Pharmacological Research Communications</SO>
<YR>1982</YR>
<VL>14</VL>
<PG>879-908</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gryglewski-1983" NAME="Gryglewski 1983" TYPE="JOURNAL_ARTICLE">
<AU>Gryglewski RJ, Nowak S, Kostka-Trabka E, Kusmiderski J, Dembinska-Kiec A, Bieron K, et al</AU>
<TI>Treatment of ischaemic stroke with prostacyclin</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-1993" NAME="Martindale 1993" TYPE="BOOK">
<AU>Reynolds JEF (ed)</AU>
<SO>Martindale, the extra pharmacopoeia</SO>
<YR>1993</YR>
<EN>30th</EN>
<PB>The Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1984" NAME="Miller 1984" TYPE="JOURNAL_ARTICLE">
<AU>Miller VT, Coull BM, Yatsu FM, Shah AB, Beamer NB</AU>
<TI>Prostacyclin infusion in acute cerebral infarction</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>1431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1985" NAME="Miller 1985" TYPE="BOOK_SECTION">
<AU>Miller VT, Coull BM, Yatsu FM, Shah AB, Beamer NB</AU>
<TI>Prostacyclin therapy for acute stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1985</YR>
<PG>235-9</PG>
<ED>Plum F, Pulsinelli W</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncada-1983" NAME="Moncada 1983" TYPE="JOURNAL_ARTICLE">
<AU>Moncada S</AU>
<TI>Biology and therapeutic potential of prostacyclin</TI>
<SO>Stroke</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>157-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sinzinger-1981" NAME="Sinzinger 1981" TYPE="JOURNAL_ARTICLE">
<AU>Sinzinger H, Silberbauer K, Horsch AK, Gall A</AU>
<TI>Decreased sensitivity of human platelets to PGI2 during long-term intra-arterial PGI2 infusion in patients with peripheral vascular disease - a rebound phenomenon?</TI>
<SO>Prostaglandins</SO>
<YR>1981</YR>
<VL>21</VL>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-17 15:12:59 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-09-17 15:12:59 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-09-17 15:12:44 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hsu-1986">
<CHAR_METHODS MODIFIED="2008-09-17 15:01:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation technique not stated<BR/>Double-blind, placebo-controlled trial<BR/>Analysis by intention to treat<BR/>Stratified by thrombotic and embolic CI<BR/>Five centre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 15:01:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>USA<BR/>49 males, 31 females<BR/>Mean age 64 years<BR/>Stroke type: atherothrombotic 66, embolic 14<BR/>Enrolment within 24 hours<BR/>100% CT pre-entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 15:12:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PGI2 (epoprostenol sodium, Upjohn Co, USA, and Wellcome, Foundation, UK)<BR/>Pl: buffer/diluent</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 15:01:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 4 weeks<BR/>Neurological impairment assessed using Turnhill score at entry, day 3, weeks 1, 2 + 4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 15:01:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: stupor, coma, psychiatric disorder, clinical intracranial hypertension, organ or systemic disease, bleeding risk, heparin<BR/>FU: 4 weeks<BR/>Further information unavailable because original data discarded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 15:02:43 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Huczynski-1985">
<CHAR_METHODS MODIFIED="2008-09-17 15:02:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation technique not stated<BR/>Double-blind, placebo controlled<BR/>No loss to FU</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 15:02:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Poland<BR/>15 male, 11 female<BR/>Mean age 67 years<BR/>Enrolment between 48 hours and 5 days<BR/>100% EEG and CSF pre-entry diagnosis of CI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 15:02:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PGI2 (epoprostenol, Wellcome, UK, and Upjohn Co, USA), 5 x 6 hour consecutive 2.5 to 5 ng/kg/min iv infusions (depending on patients tolerance), separated by 6 hour intervals<BR/>Pl: solvent<BR/>Duration: 54 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 15:02:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 2 weeks<BR/>Neurological impairment assessed using modified Matthew score at baseline, after 6 and 54 hours, 2 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 15:02:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: heart failure, hyperglycaemia, uraemia, hyperpyrexia, previous stroke<BR/>FU: 2 weeks<BR/>Further information unavailable since original data discarded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 15:03:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Huczynski-1988">
<CHAR_METHODS MODIFIED="2008-09-17 15:02:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation technique not stated<BR/>Double-blind, placebo controlled<BR/>Not intention-to-treat<BR/>Withdrawals: PGI2 4, Pl 1 from treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 15:03:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>Poland<BR/>16 male, 14 female<BR/>Mean age 61 years<BR/>Enrolment 24 to 72 hours after CI<BR/>100% EEG and CSF pre-entry diagnosis of CI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 15:03:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PGI2 (Wellcome, UK, or Chinoin, WRL), daily 6 hour iv infusions at 2.5 to 5 ng/kg/ min<BR/>Pl: glycine solvent<BR/>Duration: 2 weeks<BR/>All patients given low molecular weight dextran</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 15:03:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 4 weeks<BR/>Neurological impairment assessed using modified Matthew score assessed at baseline, after each infusion, 3 and 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 15:03:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: heart failure, hyperglycaemia, uraemia, arrhythmia, hyperpyrexia, previous stroke, mild stroke<BR/>FU: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 15:04:35 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Martin-1985">
<CHAR_METHODS MODIFIED="2008-09-17 15:03:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation technique not stated (randomisation in blocks of 4)<BR/>Double-blind, placebo-controlled<BR/>Not intention-to-treat<BR/>Withdrawal: PGI2 1 from treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 15:04:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>UK. 32 patients (gender numbers not given)<BR/>Mean age 68 years<BR/>Enrolment between 24 and 36 hours of stroke<BR/>100% CT exclusion of PICH</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 15:04:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PGI2 (epoprostenol, Wellcome, UK), 5 x 6 hour alternating prostacyclin 5 ng/kg/min and saline iv infusions<BR/>Pl: solvent<BR/>Duration: 54 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 15:04:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 2 weeks and 10 to 18 months<BR/>Neurological impairment assessed using modified Matthew Score, Token speech test, and WHO disability status at 2 and 4 weeks<BR/>CT infarct volume at 2 weeks<BR/>Cerebral blood transit time pre and post-infusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 15:04:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: ICH<BR/>FU: 2 weeks and 10 to 18 months<BR/>Further information unavailable since original data discarded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 15:05:14 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Pokrupa-1986">
<CHAR_METHODS MODIFIED="2008-09-17 15:04:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomisation by sealed numbered opaque envelope<BR/>Double-blind, placebo-controlled, single-centre trial<BR/>Intention-to-treat<BR/>No loss to FU</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 15:04:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>Canada<BR/>11 male, 12 female<BR/>Mean age 63 years<BR/>100% CT pre-entry<BR/>Enrolment within 48 hours of ictus</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 15:04:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PGI2 ("Cycloprostin", Upjohn Co., USA) 5 daily 8 hour consecutive infusions weaned up from 2 to 10 ng/kg/min and tapered over last hour<BR/>Pl: sterile diluent buffer (NaCl 0.147 w/v, glycine 0.188 w/v, NaOH, pH 10.5 +/- 0.3)<BR/>Duration: 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 15:05:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 5 days, and 1, 2 and 4 weeks<BR/>Neurological impairment rating at 5 days, and 1, 2 and 4 weeks<BR/>CT and PET at 5 to 9 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 15:05:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: coma, complicating neurological conditions, heparin, malignant hypertension, uncontrolled diabetes mellitus, heart attack within 2 months, recent surgery<BR/>FU: 5 days, and 1, 2, and 4 weeks<BR/>Original data available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CI: cerebral infarction<BR/>Ex: exclusion<BR/>FU: follow up<BR/>PICH: primary intracerebral haemorrhage<BR/>iv: intravenous<BR/>PGI2: prostacyclin<BR/>Pl: placebo<BR/>Rx: treatment</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-09-17 15:06:15 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-17 15:05:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hakim-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 15:05:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>5 patients with acute ischaemic stroke (&lt; 48 hours of onset) given prostacyclin (2 to 10 ng/kg/min iv over 8 hours daily for 5 days)<BR/>Excluded: non-controlled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 15:05:57 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hoshi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 15:05:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Patients post cerebral infarction<BR/>Excluded: (i) cross-over trial; (ii) one month post stroke, i.e. trial not acute</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 15:06:05 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Isaka-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 15:06:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>5 patients with carotid atheroma post ischaemic stroke<BR/>Assessment of carotid platelet deposition (indium 111 scintigraphy) on TRK-100 or placebo<BR/>Excluded: (i) crossover trial; (ii) no relevant outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 15:06:09 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Mizushima-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 15:06:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>Patients with mixed group of diagnoses<BR/>Excluded: (i) data relating to stroke patients unavailable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 15:06:15 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhao-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 15:06:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>18 patients with acute cerebral infarction (&lt; 72 hours of onset) given prostacyclin (2-5 ng/kg/min iv; n = 11) versus dextran (n = 7)<BR/>Excluded: (i) confounded; (ii) not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hsu-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huczynski-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huczynski-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martin-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pokrupa-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Prostacyclin vs control in ischaemic stroke: all trials</NAME>
<DICH_OUTCOME CHI2="0.784268181446893" CI_END="1.8513941248472907" CI_START="0.21604766726879737" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6324471376078903" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.26749888121974796" LOG_CI_START="-0.6654504185346922" LOG_EFFECT_SIZE="-0.1989757686574721" METHOD="PETO" NO="1" P_CHI2="0.8532261026490984" P_Q="1.0" P_Z="0.4031397964656799" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="93" WEIGHT="100.0" Z="0.8360268676282117">
<NAME>All cause case fatality, early (within 4 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.73975951757274" CI_START="0.17422332711647917" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7588936968615585" LOG_CI_START="-0.7588936968615584" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.8915558282417286" STUDY_ID="STD-Martin-1985" TOTAL_1="16" TOTAL_2="16" VAR="1.2580645161290323" WEIGHT="37.78280556522254"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Huczynski-1985" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.289760927261314" CI_START="0.043219303746673564" EFFECT_SIZE="0.43058156081736565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6324330891860412" LOG_CI_START="-1.3643222337834877" LOG_EFFECT_SIZE="-0.36594457229872324" ORDER="3" O_E="-0.6125" SE="1.1729039608105587" STUDY_ID="STD-Hsu-1986" TOTAL_1="43" TOTAL_2="37" VAR="0.7269007120253164" WEIGHT="21.83063580251038"/>
<DICH_DATA CI_END="16.79145288401582" CI_START="0.05955410808744988" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2250882751858339" LOG_CI_START="-1.2250882751858336" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="1.439245834257849" STUDY_ID="STD-Huczynski-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="14.498441746513333"/>
<DICH_DATA CI_END="2.862842755673138" CI_START="0.04199367974363257" EFFECT_SIZE="0.3467294360710038" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45679749464441105" LOG_CI_START="-1.3768160681499841" LOG_EFFECT_SIZE="-0.4600092867527866" ORDER="113366" O_E="-0.9130434782608696" SE="1.077073683318948" STUDY_ID="STD-Pokrupa-1986" TOTAL_1="11" TOTAL_2="12" VAR="0.8620037807183364" WEIGHT="25.888116885753757"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.912111301979369" CI_START="0.25561644922884497" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5924112022371992" LOG_CI_START="-0.5924112022371992" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>All cause case fatality, late (up to 18 months)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.912111301979369" CI_START="0.25561644922884497" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5924112022371992" LOG_CI_START="-0.5924112022371992" LOG_EFFECT_SIZE="0.0" ORDER="113371" O_E="0.0" SE="0.6959705453537527" STUDY_ID="STD-Martin-1985" TOTAL_1="16" TOTAL_2="16" VAR="2.064516129032258" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>